TNSN07275A1 - Derives de triazole substitues, servant d'antagonistes d'ocytocine - Google Patents
Derives de triazole substitues, servant d'antagonistes d'ocytocineInfo
- Publication number
- TNSN07275A1 TNSN07275A1 TNP2007000275A TNSN07275A TNSN07275A1 TN SN07275 A1 TNSN07275 A1 TN SN07275A1 TN P2007000275 A TNP2007000275 A TN P2007000275A TN SN07275 A TNSN07275 A TN SN07275A TN SN07275 A1 TNSN07275 A1 TN SN07275A1
- Authority
- TN
- Tunisia
- Prior art keywords
- ocytocin
- antagonists
- triazole derivatives
- substituted triazole
- substituted
- Prior art date
Links
- 102400000050 Oxytocin Human genes 0.000 title 1
- 101800000989 Oxytocin Proteins 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 title 1
- 229940042055 systemic antimycotics triazole derivative Drugs 0.000 title 1
- 201000001880 Sexual dysfunction Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 231100000872 sexual dysfunction Toxicity 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 150000003852 triazoles Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Reproductive Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La présente invention concerne des triazoles substitués de formule (I), leurs utilisations, des procédés pour leur préparation et des compositions contenant lesdits composés. Ces inhibiteurs sont utiles dans divers domaines thérapeutiques, y compris un dysfonctionnement sexuel.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0501190.3A GB0501190D0 (en) | 2005-01-20 | 2005-01-20 | Novel pharmaceuticals |
| PCT/IB2006/000118 WO2006077496A1 (fr) | 2005-01-20 | 2006-01-11 | Utilisation de derives de triazole substitues comme antagonistes de l'oxytocine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TNSN07275A1 true TNSN07275A1 (fr) | 2008-12-31 |
Family
ID=34259404
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TNP2007000275A TNSN07275A1 (fr) | 2005-01-20 | 2007-07-19 | Derives de triazole substitues, servant d'antagonistes d'ocytocine |
Country Status (31)
| Country | Link |
|---|---|
| US (5) | US7557131B2 (fr) |
| EP (1) | EP1841758B1 (fr) |
| JP (1) | JP4124805B1 (fr) |
| KR (1) | KR100936854B1 (fr) |
| CN (1) | CN101107243B (fr) |
| AP (1) | AP2007004047A0 (fr) |
| AR (1) | AR055303A1 (fr) |
| AT (1) | ATE449091T1 (fr) |
| AU (1) | AU2006207300B2 (fr) |
| BR (1) | BRPI0606463A2 (fr) |
| CA (1) | CA2595569C (fr) |
| CR (1) | CR9219A (fr) |
| DE (1) | DE602006010508D1 (fr) |
| DK (1) | DK1841758T3 (fr) |
| DO (1) | DOP2006000014A (fr) |
| EA (1) | EA200701328A1 (fr) |
| ES (1) | ES2334517T3 (fr) |
| GB (1) | GB0501190D0 (fr) |
| GT (1) | GT200600024A (fr) |
| IL (1) | IL184148A (fr) |
| MA (1) | MA29160B1 (fr) |
| MX (1) | MX2007008757A (fr) |
| NL (1) | NL1030961C2 (fr) |
| NO (1) | NO338420B1 (fr) |
| PA (1) | PA8660401A1 (fr) |
| PE (1) | PE20060875A1 (fr) |
| TN (1) | TNSN07275A1 (fr) |
| TW (1) | TW200637847A (fr) |
| UY (1) | UY29339A1 (fr) |
| WO (1) | WO2006077496A1 (fr) |
| ZA (1) | ZA200705718B (fr) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06284516A (ja) * | 1993-03-31 | 1994-10-07 | Mitsubishi Electric Corp | 電気車制御装置 |
| AP2007004047A0 (en) | 2005-01-20 | 2007-06-30 | Pfizer Ltd | Substituted triazole derivatives as oxtocin antagonists |
| GB0504556D0 (en) * | 2005-03-04 | 2005-04-13 | Pfizer Ltd | Novel pharmaceuticals |
| EP1902051A1 (fr) * | 2005-06-09 | 2008-03-26 | Merck Frosst Canada Ltd. | Derives d'azacyclohexane comme inhibiteurs de la stearoyl-coenzyme a delta-9 desaturase |
| GB0607196D0 (en) * | 2006-04-11 | 2006-05-17 | Prosidion Ltd | G-protein coupled receptor agonists |
| WO2007143823A1 (fr) * | 2006-06-12 | 2007-12-21 | Merck Frosst Canada Ltd. | Dérivés d'azétidine comme inhibiteurs de la stéaroyl-coenzyme a delta-9 désaturase |
| CA2654098A1 (fr) * | 2006-06-13 | 2007-12-21 | Merck Frosst Canada Ltd. | Derives de l'azacyclopentane utilises en tant qu'inhibiteurs de la stearoyl-coenzyme a delta-9 desaturase |
| WO2008133975A1 (fr) * | 2007-04-26 | 2008-11-06 | Avalon Pharmaceuticals | Composés polycycliques et leurs utilisations |
| AU2009210296B2 (en) | 2008-01-31 | 2013-11-14 | Sanofi | Cyclic azaindole-3-carboxamides, their preparation and their use as pharmaceuticals |
| EP2247575B1 (fr) | 2008-01-31 | 2016-03-23 | Sanofi | Indole-3-carboxamides cycliques, leur preparation et leur utilisation comme produits pharmaceutiques |
| MX350922B (es) * | 2012-07-16 | 2017-09-25 | Fibrogen Inc | Proceso para elaborar compuestos de isoquinolina. |
| US10570146B2 (en) | 2014-07-25 | 2020-02-25 | Northeastern University | Urea/carbamates FAAH MAGL or dual FAAH/MAGL inhibitors and uses thereof |
| JOP20190072A1 (ar) | 2016-10-13 | 2019-04-07 | Glaxosmithkline Ip Dev Ltd | مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم |
| US10875829B1 (en) | 2016-11-18 | 2020-12-29 | Integrative Research Laboratories Sweden Ab | Azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission |
| CN108884071B (zh) * | 2016-12-21 | 2021-05-14 | 江苏恒瑞医药股份有限公司 | 稠环基氮杂环丁基三唑类衍生物、其制备方法及其在医药上的应用 |
| EP3564231A4 (fr) * | 2016-12-28 | 2020-08-12 | Jiangsu Hengrui Medicine Co., Ltd. | Dérivé de triazole azabicyclo-substitué, sa méthode de préparation et son application en médecine |
| CN111094272B (zh) * | 2018-06-20 | 2022-05-27 | 江苏恒瑞医药股份有限公司 | 一种otr抑制剂的可药用盐、晶型及制备方法 |
| TW202016092A (zh) * | 2018-06-20 | 2020-05-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | Ｏｔｒ抑制劑的晶型及其製備方法 |
| WO2020001460A1 (fr) * | 2018-06-27 | 2020-01-02 | 江苏恒瑞医药股份有限公司 | Sel pharmaceutiquement acceptable, forme cristalline d'un dérivé de triazole substitué par azabicyclo et procédé de préparation |
| CN113004250B (zh) * | 2019-12-19 | 2022-07-26 | 上海森辉医药有限公司 | 一种制备取代的三唑衍生物的方法 |
| CN113582818B (zh) * | 2021-08-30 | 2023-08-01 | 上海日异生物科技有限公司 | 一种3-卤-2-烷基苯酚的合成方法 |
| US20250152585A1 (en) * | 2022-02-16 | 2025-05-15 | Duke Street Bio Limited | Pharmaceutical compound |
| CN114805161B (zh) * | 2022-06-14 | 2023-08-25 | 南通华祥医药科技有限公司 | 一种3-氟丫丁啶盐酸盐的制备方法 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4554276A (en) | 1983-10-03 | 1985-11-19 | Pfizer Inc. | 2-Amino-5-hydroxy-4-methylpyrimidine derivatives |
| US5053411A (en) | 1989-04-20 | 1991-10-01 | Anaquest, Inc. | N-aryl-N-[4-(1-heterocyclicalkyl)piperidinyl]amides and pharmaceutical compositions and methods employing such compounds |
| DE4124942A1 (de) | 1991-07-27 | 1993-01-28 | Thomae Gmbh Dr K | 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| DE4302051A1 (de) | 1993-01-26 | 1994-07-28 | Thomae Gmbh Dr K | 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| AU714851B2 (en) | 1996-04-03 | 2000-01-13 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| WO1997036876A1 (fr) | 1996-04-03 | 1997-10-09 | Merck & Co., Inc. | Inhibiteurs de la farnesyl-proteine transferase |
| EP0904076A1 (fr) | 1996-04-03 | 1999-03-31 | Merck & Co., Inc. | Inhibiteurs de la farnesyl-proteine transferase |
| JP2000509371A (ja) | 1996-04-03 | 2000-07-25 | メルク エンド カンパニー インコーポレーテッド | ファルネシル―タンパク質トランスフェラーゼ阻害剤 |
| EP1003374A1 (fr) | 1996-12-30 | 2000-05-31 | Merck & Co., Inc. | Inhibiteurs de farnesyl-proteine transferase |
| DE69833671T2 (de) | 1997-12-16 | 2006-11-30 | Pfizer Products Inc., Groton | KOMBINATION AUS EINEM ALPHA-1-ADRENOREZEPTOR ANTAGONISTEN UND EINEM CGM PDEv HEMMER ZUR BEHANDLUNG VON IMPOTENZ |
| EP1206935A4 (fr) | 1999-07-23 | 2008-07-30 | Shionogi & Co | Inhibiteurs de differenciation th2 |
| DK1224174T3 (da) | 1999-10-15 | 2004-01-26 | Hoffmann La Roche | Benzodiazepinderivater |
| JP4883862B2 (ja) | 1999-11-15 | 2012-02-22 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ファルネシルトランスフェラーゼ阻害剤としてのトリアゾール類 |
| AU2001244610A1 (en) | 2000-04-05 | 2001-10-23 | Shionogi And Co., Ltd. | Oil-in-water microemulsions containing tricyclic compounds or preconcentrates thereof |
| CA2409819C (fr) * | 2000-05-19 | 2009-09-15 | Yamanouchi Pharmaceutical Co., Ltd. | Derives de triazole |
| US20030216385A1 (en) | 2000-05-19 | 2003-11-20 | Takahiko Tobe | Triazole derivatives |
| AU2002367752A1 (en) | 2001-10-03 | 2003-11-17 | Pharmacia Corporation | Substituted 5-membered polycyclic compounds useful for selective inhibition of the coagulation cascade |
| GB0130677D0 (en) | 2001-12-21 | 2002-02-06 | Glaxo Group Ltd | Medicaments and novel compounds |
| GB0208579D0 (en) | 2002-04-13 | 2002-05-22 | British Biotech Pharm | Antibacterial agents |
| GB0224919D0 (en) | 2002-10-25 | 2002-12-04 | Pfizer Ltd | Triazole compounds useful in therapy |
| US20040167188A1 (en) | 2003-02-14 | 2004-08-26 | Zhili Xin | Protein-tyrosine phosphatase inhibitors and uses thereof |
| US7169797B2 (en) | 2003-02-14 | 2007-01-30 | Abbott Laboratories | Protein-tyrosine phosphatase inhibitors and uses thereof |
| MXPA06003158A (es) * | 2003-09-22 | 2006-06-05 | Pfizer | Derivados de triazol sustituidos como antagonistas de oxitocina. |
| GEP20084571B (en) | 2003-12-22 | 2008-12-25 | Pfizer | Triazole derivatives as vasopressin antagonists |
| WO2005082866A2 (fr) * | 2004-02-20 | 2005-09-09 | Pfizer Limited | Derives de triazole substitues utilises en tant qu'antagonistes de l'oxytocine |
| EP1742932A1 (fr) | 2004-04-28 | 2007-01-17 | Pfizer Limited | Derives 3-heterocyclyl-4-phenyl-triazole comme inhibiteurs de la vasopressine par recepteur |
| AP2007004047A0 (en) | 2005-01-20 | 2007-06-30 | Pfizer Ltd | Substituted triazole derivatives as oxtocin antagonists |
-
2005
- 2005-01-11 AP AP2007004047A patent/AP2007004047A0/xx unknown
- 2005-01-20 GB GBGB0501190.3A patent/GB0501190D0/en not_active Ceased
-
2006
- 2006-01-11 DE DE602006010508T patent/DE602006010508D1/de active Active
- 2006-01-11 JP JP2007551766A patent/JP4124805B1/ja not_active Expired - Fee Related
- 2006-01-11 MX MX2007008757A patent/MX2007008757A/es active IP Right Grant
- 2006-01-11 CN CN2006800028617A patent/CN101107243B/zh not_active Expired - Fee Related
- 2006-01-11 AU AU2006207300A patent/AU2006207300B2/en not_active Ceased
- 2006-01-11 EP EP06710261A patent/EP1841758B1/fr active Active
- 2006-01-11 AT AT06710261T patent/ATE449091T1/de not_active IP Right Cessation
- 2006-01-11 ES ES06710261T patent/ES2334517T3/es active Active
- 2006-01-11 WO PCT/IB2006/000118 patent/WO2006077496A1/fr not_active Ceased
- 2006-01-11 BR BRPI0606463-9A patent/BRPI0606463A2/pt not_active IP Right Cessation
- 2006-01-11 CA CA2595569A patent/CA2595569C/fr active Active
- 2006-01-11 DK DK06710261.6T patent/DK1841758T3/da active
- 2006-01-11 EA EA200701328A patent/EA200701328A1/ru unknown
- 2006-01-11 KR KR1020077016553A patent/KR100936854B1/ko not_active Expired - Fee Related
- 2006-01-17 DO DO2006000014A patent/DOP2006000014A/es unknown
- 2006-01-17 PE PE2006000072A patent/PE20060875A1/es not_active Application Discontinuation
- 2006-01-18 AR ARP060100188A patent/AR055303A1/es unknown
- 2006-01-18 UY UY29339A patent/UY29339A1/es active IP Right Grant
- 2006-01-19 TW TW095102071A patent/TW200637847A/zh unknown
- 2006-01-19 NL NL1030961A patent/NL1030961C2/nl not_active IP Right Cessation
- 2006-01-19 GT GT200600024A patent/GT200600024A/es unknown
- 2006-01-20 US US11/335,940 patent/US7557131B2/en active Active
- 2006-01-20 PA PA20068660401A patent/PA8660401A1/es unknown
-
2007
- 2007-06-21 IL IL184148A patent/IL184148A/en active IP Right Grant
- 2007-07-02 CR CR9219A patent/CR9219A/es not_active Application Discontinuation
- 2007-07-11 ZA ZA200705718A patent/ZA200705718B/xx unknown
- 2007-07-19 TN TNP2007000275A patent/TNSN07275A1/fr unknown
- 2007-07-20 MA MA30089A patent/MA29160B1/fr unknown
- 2007-08-14 NO NO20074177A patent/NO338420B1/no unknown
-
2009
- 2009-05-15 US US12/466,785 patent/US8207198B2/en not_active Expired - Fee Related
-
2012
- 2012-05-23 US US13/478,384 patent/US9023872B2/en active Active
-
2015
- 2015-04-20 US US14/691,319 patent/US9394278B2/en not_active Expired - Fee Related
-
2016
- 2016-06-28 US US15/195,480 patent/US10150752B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TNSN07275A1 (fr) | Derives de triazole substitues, servant d'antagonistes d'ocytocine | |
| TNSN07022A1 (fr) | Derives de pyridine | |
| TN2009000450A1 (fr) | Derives de pyridine | |
| MA29926B1 (fr) | Derives de pyrazine | |
| MA31766B1 (fr) | Composés organiques | |
| MA30405B1 (fr) | Derives de 4-benzylphtalazinone substitues en 2 en tant qu'antagonistes des histamines hl et h3 | |
| MA31894B1 (fr) | Composes organiques | |
| MA27728A1 (fr) | Antagonistes des recepteurs de cgrp | |
| MA33178B1 (fr) | Pipéridines substituées comme antagonistes de ccr3 | |
| MA32466B1 (fr) | Derives de triazole utiles pour le traitement de maladies | |
| DE602005020655D1 (de) | Carboxamid-spirolactam-cgrp-rezeptor-antagonisten | |
| IL182317A0 (en) | Cgrp receptor antagonists | |
| ATE466860T1 (de) | Cgrp-rezeptorantagonisten | |
| TN2011000316A1 (fr) | Derives de sulfonamides | |
| MA30351B1 (fr) | Composes de tetrahydropyridothienopyrimidine et leurs procedes d'utilisation | |
| TNSN08137A1 (fr) | Derives de carboxamides servant d'antagonistes des recepteurs muscariniques | |
| MA33836B1 (fr) | Compositions pharmaceutiques contenant des ligands des récepteurs sigma | |
| MA31761B1 (fr) | Nouveaux inhibiteurs de seh et leur utilisation | |
| ATE503755T1 (de) | Cgrp-rezeptorantagonisten | |
| BR0305708A (pt) | Derivados de benzimidazol para o tratamento de disfunção sexual | |
| WO2006041830A3 (fr) | Antagonistes du recepteur de cgrp | |
| TW200716547A (en) | Piperidin-4-yl-amide derivatives | |
| MA31863B1 (fr) | Dérivés de pyrazole comme inhibiteurs de 5-lo | |
| EP1802372A4 (fr) | Antagonistes des recepteurs du cgrp) | |
| DE602007010041D1 (de) | Imidazolidinonylaminopyrimidinverbindungen zur behandlung von krebs |